These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28391970)

  • 21. The role of activation of the 5-HT1A receptor and adenylate cyclase in the antidepressant-like effect of YL-0919, a dual 5-HT1A agonist and selective serotonin reuptake inhibitor.
    Qin JJ; Chen HX; Zhao N; Yuan L; Zhang YZ; Yang RF; Zhang LM; Li YF
    Neurosci Lett; 2014 Oct; 582():104-8. PubMed ID: 25220701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor.
    Okada M; Matsumoto R; Yamamoto Y; Fukuyama K
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Further SAR studies of piperidine-based analogues of cocaine. 2. Potent dopamine and serotonin reuptake inhibitors.
    Tamiz AP; Zhang J; Flippen-Anderson JL; Zhang M; Johnson KM; Deschaux O; Tella S; Kozikowski AP
    J Med Chem; 2000 Mar; 43(6):1215-22. PubMed ID: 10737754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.
    Wu YJ; He H; Bertekap R; Westphal R; Lelas S; Newton A; Wallace T; Taber M; Davis C; Macor JE; Bronson J
    Bioorg Med Chem; 2013 Apr; 21(8):2217-2228. PubMed ID: 23477943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and biological evaluation of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives as potential antidepressants with a dual mode of action: serotonin reuptake inhibition and 5-HT1A receptor antagonism.
    Oficialdegui AM; Martinez J; Pérez S; Heras B; Irurzun M; Palop JA; Tordera R; Lasheras B; del Río J; Monge A
    Farmaco; 2000 May; 55(5):345-53. PubMed ID: 10983279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect.
    Wróbel MZ; Chodkowski A; Herold F; Marciniak M; Dawidowski M; Siwek A; Starowicz G; Stachowicz K; Szewczyk B; Nowak G; Belka M; Bączek T; Satała G; Bojarski AJ; Turło J
    Eur J Med Chem; 2019 Dec; 183():111736. PubMed ID: 31586817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and systematic evaluation of 4-arylpiperazine- and 4-benzylpiperidine napthyl ethers as inhibitors of monoamine neurotransmitters reuptake.
    Paudel S; Min X; Acharya S; Khadka DB; Yoon G; Kim KM; Cheon SH
    Bioorg Med Chem; 2018 Nov; 26(20):5538-5546. PubMed ID: 30293797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands.
    Zajdel P; Marciniec K; Maślankiewicz A; Paluchowska MH; Satała G; Partyka A; Jastrzębska-Więsek M; Wróbel D; Wesołowska A; Duszyńska B; Bojarski AJ; Pawłowski M
    Bioorg Med Chem; 2011 Nov; 19(22):6750-9. PubMed ID: 22001327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 5.
    Takeuchi K; Kohn TJ; Honigschmidt NA; Rocco VP; Spinazze PG; Hemrick-Luecke SK; Thompson LK; Evans DC; Rasmussen K; Koger D; Lodge D; Martin LJ; Shaw J; Threlkeld PG; Wong DT
    Bioorg Med Chem Lett; 2006 May; 16(9):2347-51. PubMed ID: 16298130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
    Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
    PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.
    Seo HJ; Park EJ; Kim MJ; Kang SY; Lee SH; Kim HJ; Lee KN; Jung ME; Lee M; Kim MS; Son EJ; Park WK; Kim J; Lee J
    J Med Chem; 2011 Sep; 54(18):6305-18. PubMed ID: 21823597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.
    Sánchez C; Bergqvist PB; Brennum LT; Gupta S; Hogg S; Larsen A; Wiborg O
    Psychopharmacology (Berl); 2003 Jun; 167(4):353-62. PubMed ID: 12719960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, Sustainable Synthesis and Biological Evaluation of a Novel Dual α2A/5-HT7 Receptor Antagonist with Antidepressant-Like Properties.
    Canale V; Kotańska M; Dziubina A; Stefaniak M; Siwek A; Starowicz G; Marciniec K; Kasza P; Satała G; Duszyńska B; Bantreil X; Lamaty F; Bednarski M; Sapa J; Zajdel P
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34201675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine augments the effect of selective serotonin reuptake inhibitors by suppressing GABAergic inhibition via antagonism of 5-HT₆ receptors in the dorsal raphe nucleus.
    Asaoka N; Nagayasu K; Nishitani N; Yamashiro M; Shirakawa H; Nakagawa T; Kaneko S
    Neuropharmacology; 2015 Aug; 95():261-8. PubMed ID: 25863120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and antidepressant effect of novel aralkyl piperazine and piperidine derivatives targeting SSRI/5-HT
    Gu ZS; Wang WT; Qian H; Zhou AN; Sun HB; Zhang QW; Li JQ
    Bioorg Med Chem Lett; 2019 Dec; 29(23):126703. PubMed ID: 31627993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
    Andrews M; Brown A; Chiva JY; Fradet D; Gordon D; Lansdell M; MacKenny M
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5893-7. PubMed ID: 19740658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats.
    Jastrzębska-Więsek M; Siwek A; Partyka A; Antkiewicz-Michaluk L; Michaluk J; Romańska I; Kołaczkowski M; Wesołowska A
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):839-49. PubMed ID: 27106213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of 5-HT(2a) and 5-HT(2B/2C) receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors.
    McMahon LR; Cunningham KA
    Neuropsychopharmacology; 2001 Mar; 24(3):319-29. PubMed ID: 11166521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electrophysiological, and behavioral characterization.
    Gobert A; Brocco M; Dekeyne A; Di Cara B; Bouchez G; Lejeune F; Gannon RL; Millan MJ
    Neuropsychopharmacology; 2009 Mar; 34(4):1039-56. PubMed ID: 18830239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants.
    Matzen L; van Amsterdam C; Rautenberg W; Greiner HE; Harting J; Seyfried CA; Böttcher H
    J Med Chem; 2000 Mar; 43(6):1149-57. PubMed ID: 10737747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.